Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2003
03/13/2003WO2003020710A1 Benzothiazepine derivatives
03/13/2003WO2003020702A2 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
03/13/2003WO2003020697A1 C2-disubstituted indane-1-ones and their derivatives, method for their production and their use as medicaments
03/13/2003WO2003020695A1 C2-disubstituted indane-1-ol systems, method for their production and their use as medicaments
03/13/2003WO2003020371A2 Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer
03/13/2003WO2003020370A1 Method for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo- and hydroxy-substituted hydrocarbons
03/13/2003WO2003020316A1 Materials sustainedly releasing drug in vivo
03/13/2003WO2003020315A1 Medicinal compositions containing angiotensin ii receptor antagonist
03/13/2003WO2003020314A1 Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
03/13/2003WO2003020310A1 Preventives and/or remedies for diseases caused by endosteal microcirculatory disorders
03/13/2003WO2003020299A1 L-methionine as a stabilizer for nesp/epo in hsa-free formulations
03/13/2003WO2003020298A1 Optimal compositions and methods thereof for treating hcv infections
03/13/2003WO2003020289A1 Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
03/13/2003WO2003020287A2 Methods for the treatment of chronic pain anc compositions therefor
03/13/2003WO2003020281A1 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma
03/13/2003WO2003020280A2 Compositions and use thereof in the treatment of cancer
03/13/2003WO2003020272A1 Compositions and methods for the treatment of cancer
03/13/2003WO2003020269A1 Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
03/13/2003WO2003020267A1 Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration
03/13/2003WO2003020262A2 Use of polyunsaturated fatty acids for intra-arterial injection for selectively occluding blood supplies to neoplasias
03/13/2003WO2003020260A1 Arginine compositions for coordinate modification of multiple cardiovascular risk factors
03/13/2003WO2003020259A2 Combinations of dmxaa and other anti-cancer agents
03/13/2003WO2003020257A2 USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
03/13/2003WO2003020252A2 Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
03/13/2003WO2003020250A1 Plaster for the treatment of dysfunctions and disorders of nail growth
03/13/2003WO2003020248A1 Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
03/13/2003WO2003020243A1 Combination dosage form containing a cholesterol -lowering agent , an inhibitor of the renin-angiotensin, and aspirin
03/13/2003WO2003020240A2 Therapeutic agent delivery tampon
03/13/2003WO2003020227A1 Compositions and methods relating to prevention of chemotherapy-induced alopecia
03/13/2003WO2003020219A2 Aerosolized decongestants for the treatment of sinusitis
03/13/2003WO2003020216A1 Methods for inhibiting cognitive deterioration in adults with down's syndrome
03/13/2003WO2003020208A2 Treatment of neurologic hemorrhage
03/13/2003WO2003020206A2 Use of atazanavir in hiv therapy
03/13/2003WO2003020202A2 Method for reducing hypertension and heart failure
03/13/2003WO2003020172A1 An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
03/13/2003WO2003020106A2 Composite staple for completing an anastomosis
03/13/2003WO2003020037A1 Multivesicular emulsion topical delivery systems
03/13/2003WO2003020026A1 Methods for treating disorders using plant extracts
03/13/2003WO2002098416A3 Antineoplastic combinations
03/13/2003WO2002089796A3 Methods for selective immunomodulation using pimecrolimus
03/13/2003WO2002089757A3 Use of isoflavones in cosmetic or dermatological preparations
03/13/2003WO2002089743A3 Use of compositions for treating rosacea
03/13/2003WO2002088080A3 Dual inhibitors of pde 7 and pde 4
03/13/2003WO2002087513A3 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
03/13/2003WO2002078625A3 Therapeutic combinations for cardiovascular and inflammatory indications
03/13/2003WO2002077217A3 Human dual specificity protein phosphatase 7-like protein
03/13/2003WO2002076548A3 Methods and apparatus for treating diseased tissue
03/13/2003WO2002074343A3 The use of non-digestible polymeric foams to sequester ingested materials, thereby inhibiting their absorption by the body
03/13/2003WO2002074291A3 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor
03/13/2003WO2002074158A3 Two-phase processing of thermosensitive polymers for use as biomaterials
03/13/2003WO2002072543A3 Rxr activating molecules
03/13/2003WO2002068654A3 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
03/13/2003WO2002068388A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists
03/13/2003WO2002068015A3 Modular infusion device and method
03/13/2003WO2002067902A3 Modulation of release from dry powder formulations
03/13/2003WO2002067760A3 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
03/13/2003WO2002066469A3 Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
03/13/2003WO2002066427A3 (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof
03/13/2003WO2002064629A3 Isolated human transporter proteins, nucleic acid molecules encoding them and uses thereof
03/13/2003WO2002060459A3 Use of iodide salt as an aphrodisiac
03/13/2003WO2002058696A3 The use of substituted azetidinone compounds for the treatment of sitosterolemia
03/13/2003WO2002052270A3 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
03/13/2003WO2002050286A3 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
03/13/2003WO2002048363A3 Human transporter proteins, nucleic acid molecules encoding them, and uses thereof
03/13/2003WO2002047662A3 Antibiotic/benzoyl peroxide dispenser
03/13/2003WO2002046461A3 Method for identifying modulators of transcription
03/13/2003WO2002046407A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/13/2003WO2002044364A3 Polypeptides involved in immune response
03/13/2003WO2002043763A3 Combination of gaba agonists and aldose reductase inhibitors
03/13/2003WO2002043762A3 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
03/13/2003WO2002042456A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/13/2003WO2002042332A3 Truncated cd200
03/13/2003WO2002039990A3 Method for screening anti-proliferative compounds and inhibiting tumor growth
03/13/2003WO2002038140A3 Therapeutic uses for ip3 receptor-mediated calcium channel modulators
03/13/2003WO2002036829A3 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
03/13/2003WO2002034288A3 Vaccine for treating allergy
03/13/2003WO2002032411A3 Combination of statins and sorbitol dehydrogenase inhibitors
03/13/2003WO2002031511A3 Modulation of ligand binding/enzymatic activity of alpha beta proteins
03/13/2003WO2002030465A3 Compositions that inhibit proliferation of cancer cells
03/13/2003WO2002026984A3 Potassium channel interactors and uses therefor
03/13/2003WO2002024920A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
03/13/2003WO2002024194A3 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
03/13/2003WO2002024179A3 Method for reducing toxicity of combined chemotherapies
03/13/2003WO2002024177A3 Methods of identifying inhibitory compounds and uses thereof
03/13/2003WO2002022151A3 Use of glp-1 and flp-2 peptides for treatment of bone disorders
03/13/2003WO2002020757A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/13/2003WO2002020056A3 Methods and compositions for producing a neurosalutary effect in a subject
03/13/2003WO2002017949A3 Novel functions for dp214
03/13/2003WO2002016416A3 Diagnosis and treatment of cardiovascular conditions
03/13/2003WO2002015893A3 Treatment of wounds
03/13/2003WO2002013866A3 Stimulating neutrophil function to treat inflammatory bowel disease
03/13/2003WO2002013803A3 Chelerythrine-based therapies for cancer
03/13/2003WO2002013797A3 Therapeutic combination of a cetp inhibitor and atorvastatin
03/13/2003WO2002011708A3 Methods for inducing apolipoprotein e secretion
03/13/2003WO2002008284A3 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
03/13/2003WO2002003684A3 Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
03/13/2003WO2002002635A3 Isolated human ion channel proteins, nucleic acid molecules encoding them, and uses thereof
03/13/2003WO2002000913A3 MODULATION OF β-AMYLOID LEVELS BY β-SECRETASE BACE2
03/13/2003WO2002000168A3 Combination hiv therapy including camptothecin
03/13/2003WO2001097848A3 Vitronectin receptor antagonist pharmaceuticals
1 ... 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 ... 1151